Dr Reddy's Launches Innovative Acid-Blocker Medication in India

In a significant move, Dr Reddy's Laboratories announced the launch of Tegoprazan in India on Tuesday. This next-generation potassium-competitive acid blocker is aimed at treating acid-related gastrointestinal diseases, such as erosive and non-erosive gastroesophageal reflux disease (GERD) and gastric ulcer.

Data reveals that acid peptic diseases affect around 38% of the Indian population, underscoring the need for effective treatment solutions. Dr Reddy's exclusive partnership with HK inno.N Corporation from South Korea plays a pivotal role in the distribution of Tegoprazan in India and selected emerging markets.

MV Ramana, CEO of Branded Markets (India and Emerging Markets), emphasized the partnership's strategic importance in addressing critical management gaps for acid peptic diseases while improving patient outcomes. Following the announcement, Dr Reddy's stock observed a 0.75% rise on the BSE.

(With inputs from agencies.)